Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 13/20 | 0.69 |
| ▸ | INSR | P06213 | 11/20 | 0.69 |
| ▸ | EGFR | P00533 | 2/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3504740 | 0.95 | IGF1R (0.69) | IGF1RINSREGFRERBB2MAPK14 | |
| SCHEMBL3506008 | 0.88 | INSR (0.68) | IGF1RINSREGFRERBB2MAPK14 | |
| SCHEMBL3504856 | 0.88 | IGF1R (0.68) | IGF1RINSREGFRERBB2MAPK14 | |
| SCHEMBL3638102 | 0.87 | INSR (0.69) | IGF1RINSREGFRERBB2MAPK14 | |
| SCHEMBL310601 | 0.87 | INSR (0.75) | IGF1RINSREGFRERBB2MAPK14 | |
| SCHEMBL3503779 | 0.86 | INSR (0.69) | IGF1RINSREGFRERBB2MAPK14 | |
| SCHEMBL3503537 | 0.84 | IGF1R (0.66) | IGF1RINSREGFRERBB2MAPK14 | |
| SCHEMBL310724 | 0.83 | INSR (0.77) | IGF1RINSREGFRERBB2MAPK14 | |
| SCHEMBL10256551 | 0.82 | IGF1R (0.90) | IGF1RINSREGFRERBB2MAPK14 | |
| SCHEMBL309813 | 0.81 | IGF1R (1.00) | IGF1RINSREGFRERBB2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2162454-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008150799-A1 | IMIDAZOPYRIDINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |